INTRODUCTION
Fusion between genes TMPRSS2 (transmembrane protease serine 2) and ERG (ETV related gene)
has been suggested as a novel, cancer-specific marker for prostate cancer (PCa) 1 . With the high prevalence of PCa, it may be the most common cancer-associated genetic rearrangement as studies have shown it to be present in about 40-70% of PCa cases. This gene fusion has been identified in a subset of prostatic tumors with potentially distinct disease characteristics. The details of those characteristics are still debated as contradictory results on different transcript isoforms and their effects on prognosis have been reported 2, 3 . The cancer specificity of this gene fusion has been questioned as TMPRSS2-ERG expression has been detected also in histologically benign tissue of cancerous prostates 4, 5, 6 , but cancer-related changes of gene expression in non-neoplastic tissue of cancer-affected prostates are not unheard of and have been reported for other biomarkers as well 7, 8, 9 .
Another subgroup of PCa was suggested when SPINK1 mRNA, often studied in conjunction with pancreatic diseases but also overexpressed in PCa 10 , was found to be overexpressed preferentially in cancers lacking TMPRSS2-ERG fusion 11, 12 . However, a recent study by Leinonen et al contradicts this by showing no signs of their mutually exclusive expression 13 .
As most of the previous TMPRSS2-ERG studies have been DNA-and FISH-based, we set out to study the mRNA transcript levels of the fusion gene, targeting two of the over 20 transcript isoforms that have been reported 14 : transcripts III and VI. TMPRSS2-ERG III is the most commonly expressed isoform 1 and TMPRSS2-ERG VI was chosen for its claimed association with aggressive disease 15 . For this purpose, we developed highly sensitive, truly quantitative and internally standardized reverse-transcription PCR (RT-qPCR) assays for both TMPRSS2-ERG transcript isoforms as well as for SPINK1 mRNA, employing a previously described assay concept 16 . The mRNA levels of these three markers were measured in 86 cancerous prostate tissues and 88
histologically benign prostate tissues (HBP) from 87 PCa patients, and in prostatic tissue specimens obtained by cystoprostatectomy from 19 patients with invasive cancer of the urinary bladder and with no history of PCa. In addition to measuring the absolute levels of expression with a truly quantitative method, our aim was to find out whether the previously reported 4, 5, 6 , occasional presence of the gene fusion in benign tissue in men with PCa was evidence of a field effect or due to the gene fusion not being truly cancer specific. We also sought to explore the claimed mutual exclusivity between SPINK1 and TMPRSS2-ERG fusion gene and whether there were alterations in their expression levels correlating to the neoplastic characteristics of the tissue. Association with PCa stage and tumor percentage was also assessed for all transcripts.
Our previously reported data on higher-than-expected levels of PCA3 in HBP tissue of canceraffected prostates compared to cancerous tissues 17 raised questions on the field effect hypothesis regarding that gene. Those issues were also explored further in this study by measuring the mRNA levels of PCA3 in the 19 cystoprostatectomy specimens and by comparing those levels to the previously obtained values of PCA3 expression in HBP and cancerous tissue of these 87 PCa patients.
MATERIALS AND METHODS

Tissue samples
We 
RNA extraction and reverse transcription
All tissue samples were processed as previously described 18 . RNA extraction protocol included the addition of a known amount of artificial RNA 19 to the samples to act as an internal control, tracking the inherent loss of RNA material throughout the process.
Real-time qPCR
Expression levels of SPINK1 and PCA3 mRNAs and TMPRSS2-ERG fusion transcripts types III and VI were measured with optimized RT-qPCR assays using target-specific oligonucleotide probes and time-resolved fluorometry in detection as described previously 18 and in Supplemental Tables 2,   3 , and 4. KLK3 mRNA levels were also determined with an RT-qPCR assay with the same concept 16, 21, 22 to ensure the presence of prostate cells. Data analysis is described in detail in Supplemental Data 1.
RESULTS
KLK3
There were no significant differences in KLK3 mRNA levels when we compared the expression in cancerous versus HBP tissue from RP specimens (p=0.2) from men with clinically localized PCa as previously reported 17 . However, KLK3 expression tended to be higher in HBP tissue from RP compared to cystoprostatectomy specimens (p=0.032).
TMPRSS2-ERG
Overall, there was evidence of TMPRSS2-ERG III expression in 55/87 (63%) and TMPRSS2-ERG VI expression in 51/87 (59%) men with clinically localized PCa. Individual tissue samples contained either both of the fusion transcript types, only one of them or neither. Both transcripts were detected in 43/87 (49%) patients, with at least one of the fusion transcripts detected in 63/87 (72%) of these patients.
Of the 88 HBP tissue samples from RP specimens from men with clinically localized PCa, more than half (45/88 or 51%) showed expression of at least one of the TMPRSS2-ERG transcripts ( Table   1 ). Expression of either or both of the TMPRSS2-ERG transcripts was detected in 57/86 (66%) cancerous tissue samples from the RP specimens. By contrast, TMPRSS2-ERG expression was not detected in prostatic tissue from 17 patients with invasive bladder cancer treated with cystoprostatectomy, whereas it was detectable in prostate tissue from two cystoprostatectomy specimens which contained foci of incidental PCa elsewhere in the gland.
Trends of field effect were observed particularly in the paired samples. Of the 48 men from whom Within the samples where TMPRSS2-ERG VI mRNA was detectable, isoform VI levels were statistically significantly higher if the same sample also showed detectable III isoform expression ( Figure 2 ). This phenomenon was seen both in cancerous (p=0.004 by Mann-Whitney) and HBP samples (p=0.001). However, no statistically significant difference (p=0.18) was observed in TMPRSS2-ERG III levels regarding whether the samples also expressed TMPRSS2-ERG VI or not ( Figure 2 ).
TMPRSS2-ERG expression did not associate with Gleason grade of the tissue sample (p=0.5 for both III and VI) but advanced pathologic stage was positively associated with the presence of TMPRSS2-ERG III (p=0.003), and TMPRSS2-ERG VI mRNAs (p=0.020) (Supplemental Table 7 ).
There was no significant association between TMPRSS2-ERG III and VI mRNA levels and the cancer cell percentage of the tissue samples (p=0.8 and p=0.7, respectively).
SPINK1
All samples except one cystoprostatectomy sample contained measurable SPINK1 mRNA ( Figure   3 ). The cancerous tissue from RP specimens had significantly higher mRNA levels (2.9-fold difference in medians, p=0.047) than the HBP tissue of RP specimens from men with clinically localized PCa. Furthermore, SPINK1 mRNA levels were statistically significantly lower in the cystoprostatectomy samples than in the HBP samples from RP specimens (3.4-fold difference in medians, p=0.010 after adjusting for clustering). The difference in median expression between cancerous tissue of RP specimens and cystoprostatectomy samples was 10-fold (p<0.001).
Neither Gleason grade of the tissue sample (p=0.4) nor advanced pathologic stage (p=0.3) was significantly associated with SPINK1 mRNA expression levels (Supplemental Table 7 ). There was no significant association between SPINK1 mRNA levels and the cancer cell percentage of the tissue samples (p=0.3).
The presence of TMPRSS2-ERG transcripts did not correlate with SPINK1 levels (p=0.8 for TMPRSS2-ERG III and p=0.6 for TMPRSS2-ERG VI), but there was a statistically significant association between SPINK1 mRNA levels and TMPRSS2-ERG III and VI levels (p=0.001 and p=0.041, respectively) in those samples where TMPRSS2-ERG fusion transcripts were detected.
PCA3
PCA3 mRNA was detectable in all 19 cystoprostatectomy samples. The median PCA3 mRNA level in those samples was 7.9x10 4 mRNA copies per µg of total RNA, which is 613-fold lower than the previously reported median PCA3 expression level in cancerous tissues 17 and 107-fold lower than the previously reported median 17 in HBP tissue of cancer-affected prostates. These differences were statistically significant (p<0.0001), but there was no statistically significant difference between PCA3 mRNA levels in cystoprostatectomy samples from cancer-free prostates (n=7) and levels in samples from prostates with incidental cancer foci elsewhere in the prostate (n=12) (p=0.18).
DISCUSSION
Although a significantly higher frequency of TMPRSS2-ERG transcripts was found in the cancerous tissue compared to the HBP tissue from the prostates harboring clinically localized cancer, the frequency of TMPRSS2-ERG expression remained high in samples from histologically benign areas.
In contrast, fusion gene transcripts were detectable only rarely in cystoprostatectomy samples from bladder cancer patients and never without concomitant incidental tumor foci present in the same prostate. Thus TMPRSS2-ERG expression can be detected in histologically normal prostate tissue obtained from a prostate in which tumors were detected. A similar trend was seen in PCA3 and SPINK1 mRNA levels.
The presence of TMPRSS2-ERG fusions has been widely considered to be a cancer-specific event 1 , but we detected TMPRSS2-ERG III and/or VI mRNAs also in 51% of HBP tissues of RP specimens from prostates with clinically localized PCa (compared to 66% in the cancerous RP samples). The phenomenon of TMPRSS2-ERG positive, benign-appearing prostate tissue has been reported before on a few occasions 4, 5, 6 . In previous studies, it has mainly been considered an anomaly, but a conceivable explanation could be a carcinogenic field effect 23 , which suggests that a larger area than just the tumor focus is originally changed in terms of neoplastic events due to a carcinogenic signal that has affected the entire area 24 . This type of area can appear histologically normal, albeit molecular changes may still be detectable. Field effect-related observations in PCa 8,9,25,26 led us to the hypothesis that the HBP tissue of PCa patients in this study may have undergone molecular changes with regard to PCA3 and SPINK1 genes and TMPRSS2-ERG fusion events even though the histological examination defined the samples as non-neoplastic. This is further supported not only by the fact that the two cystoprostatectomy samples that presented TMPRSS2-ERG expression, were taken from prostates that in pathologic sectioning studies were found to contain incidental prostate tumor foci, but also by the higher likelihood of the HBP samples to contain detectable TMPRSS2-ERG mRNA if the matched cancerous sample was also TMPRSS2-ERG fusion-positive.
The previously reported ranges of 10-100-fold overexpression of PCA3 in cancerous tissue 27, 28 did not seem to be in line with our recent results where the control tissue was HBP tissue from prostates with clinical PCa and only a 5.7-fold overexpression was observed 17 . However, in light of this study where we determined the PCA3 expression in benign prostate tissue from cystoprostatectomy specimens and compared it with the previously measured levels of PCA3 mRNA in tissue of cancer-affected prostates, the overexpression of PCA3 is more pronounced when the cancerous tissue is, in fact, compared to tissue from prostates without clinical PCa. The cohort of prostates without clinical PCa is admittedly limited in this study, but nevertheless, this suggests that the PCA3 levels may also be elevated in histologically benign areas of the cancerous prostate when compared to cancer-free prostates -as was seen here as a 107-fold difference in mRNA levels.
SPINK1 has been claimed to be overexpressed in PCa 9,29 and also to exclusively identify a subgroup of PCas lacking TMPRSS2-ERG fusion, although contradictory results have been reported as well 13 .
In this study, we did not find them to be mutually exclusive, but did observe a positive correlation between SPINK1 and TMPRSS2-ERG mRNA levels in the samples where TMPRSS2-ERG fusion transcripts were detected. However, measuring transcripts in tissue extracts does not allow a 
CONCLUSIONS
To conclude, histologically benign tissue from a prostate affected by PCa can present molecular level changes in mRNA expression regarding the fusion gene TMPRSS2-ERG and PCA3 and SPINK1 genes. Thus, molecular tools such as the markers studied here could provide a means to identify an enhanced risk of PCa or presence of already established PCa missed by the biopsy procedure. 
